Ingrezza

How Does Ingrezza Work?

Ingrezza belongs to a drug class called VMAT2 inhibitors. VMAT2 (vesicular monoamine transporter 2) is a protein in dopamine-producing nerve cells that loads dopamine into tiny storage containers (vesicles) for release into the synapse. By reversibly blocking VMAT2, Ingrezza reduces the amount of dopamine available for release.

In tardive dyskinesia, chronic antipsychotic use causes dopamine receptors to become hypersensitive. When excess dopamine binds to these oversensitive receptors, it triggers the abnormal involuntary movements of TD. By reducing dopamine release, Ingrezza calms this excessive dopamine signaling. In HD chorea, neurodegeneration creates similar dopamine dysregulation, and Ingrezza's VMAT2 inhibition reduces the chorea symptoms.

Valbenazine is a prodrug converted to its active metabolite ([+]-alpha-HTBZ) in the body. Ingrezza is highly selective for VMAT2 over other monoamine receptors — a key advantage over older drugs like tetrabenazine that have a broader and less targeted mechanism.

How Hard Is It to Find Ingrezza in Stock?

Ingrezza is not on the FDA's official drug shortage list in 2026, but patients frequently report difficulty getting it filled. The primary reason is that Ingrezza is a specialty-only medication — it cannot be dispensed at standard retail pharmacies like CVS, Walgreens (retail), or Walmart. It is only available through a select network of specialty and affiliated pharmacies enrolled in Neurocrine's Access Support program.

Additional access barriers include prior authorization requirements (required by virtually all insurance plans), the drug's high retail cost, and — for some patients — insurance step therapy requirements that may mandate trying another VMAT2 inhibitor first. These structural access challenges can make Ingrezza feel unavailable even though the drug itself is in supply.

If you're struggling to find a pharmacy that can fill your Ingrezza prescription, medfinder can help. medfinder calls pharmacies on your behalf to identify which ones can fill your prescription — you provide your medication, dose, and location, and medfinder texts you the results.

Who Can Prescribe Ingrezza?

Ingrezza is not a controlled substance and has no DEA schedule requirements. Any licensed prescriber can legally write a prescription for Ingrezza. However, some insurance prior authorization criteria specify that initial prescriptions must come from a specialist (neurologist or psychiatrist). Prescribers of Ingrezza include:

Neurologists — especially movement disorder neurologists

Psychiatrists — particularly those managing patients on antipsychotics

Movement disorder specialists — subspecialty neurologists focused on TD, HD, Parkinson's

Geriatric psychiatrists — for elderly patients with TD

Primary care physicians (PCPs) — for ongoing management after specialist initiation

Nurse practitioners (NPs) and physician assistants (PAs) — within their scope of practice in neurology or psychiatry settings

Telehealth prescribing is possible for ongoing management once a diagnosis has been established. Initial diagnosis of tardive dyskinesia or HD chorea typically requires an in-person examination. Once diagnosis is confirmed, telehealth neurology and psychiatry platforms can manage prescription renewals and dose adjustments.

Is Ingrezza a Controlled Substance?

No. Ingrezza (valbenazine) is not a controlled substance. It has no DEA schedule and does not have the prescription fill restrictions associated with Schedule II–V medications. There are no limits on how many days' supply can be prescribed at once, and refills do not require in-person visits specifically for controlled substance management.

Despite not being a controlled substance, Ingrezza requires prior authorization from insurance, is distributed only through specialty pharmacies, and carries a boxed warning for patients with Huntington's disease regarding depression and suicidal ideation — so it still requires careful prescriber oversight and monitoring.

Common Side Effects of Ingrezza

The most common side effects reported in clinical trials include:

Somnolence (drowsiness/sedation) — most common; can affect driving ability

Fatigue and tiredness

Balance and gait changes

Urticaria (hives) and rash — particularly in HD patients

Insomnia — particularly in HD patients

Serious Side Effects

Angioedema: Potentially fatal swelling of the face, lips, tongue, or airway. Stop Ingrezza and seek emergency care immediately.

Parkinson-like symptoms: Tremor, rigidity, drooling, balance problems (3–5% of patients). Reduce dose or discontinue if significant.

QT prolongation: Avoid in congenital long QT syndrome; risk increases with strong CYP inhibitors.

Neuroleptic Malignant Syndrome (NMS): Rare but serious; high fever, muscle rigidity, confusion.

Depression and suicidal ideation (HD patients): Boxed warning — monitor HD patients closely.

Final Thoughts on Ingrezza

Ingrezza (valbenazine) has been a landmark treatment since its 2017 approval as the first dedicated therapy for tardive dyskinesia. Its once-daily dosing without food requirements, high VMAT2 selectivity, and well-characterized safety profile have made it a widely used first-line treatment for TD. Its 2023 approval for HD chorea expanded its clinical utility significantly.

The main challenge with Ingrezza is not the drug's effectiveness — it's access. Specialty-pharmacy-only distribution, prior authorization requirements, and a high retail price create real barriers for patients. Most patients who qualify for and properly enroll in savings programs pay $10 or less per month, but navigating those systems takes effort and support. Neurocrine's Access Support team (1-844-647-3992) is a critical resource.

If you're having trouble finding a pharmacy that can fill your Ingrezza prescription, medfinder calls pharmacies on your behalf to locate which ones can fill your specific prescription. Provide your medication, dose, and location — and medfinder delivers the results via text.